Inozyme Pharma

79 articles about Inozyme Pharma

• Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

  5/9/2023

  Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the first quarter ended March 31, 2023, and provided business highlights.

• Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 03, 2023

  5/3/2023

  Inozyme Pharma, Inc. announced that the Company granted stock options to new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.

• Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)

  4/14/2023

  Inozyme Pharma, Inc. today announced Yves Sabbagh, Ph.D., the company’s senior vice president and chief scientific officer, will present recently announced preliminary data from the ongoing Phase 1/2 clinical trial of INZ-701 in patients with ENPP1 Deficiency in an oral presentation on Monday, April 17 at the European Calcified Tissue Society Congress (ECTS) in Liverpool, UK.

• Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference

  4/11/2023

  Inozyme Pharma, Inc. today announced Douglas A. Treco, Ph.D., the company’s chief executive officer and chairman of the board, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 from 9:30-10:10am ET.

• Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer

  4/4/2023

  Inozyme Pharma, Inc. announced the grant of an inducement award outside of the Company’s 2020 Stock Incentive Plan to its newly appointed Chief Operations Officer, Matthew Winton, Ph.D.

• Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights

  3/22/2023

  Inozyme Pharma, Inc today reported financial results for the full year ended December 31, 2022, and provided recent business highlights.

• Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference

  3/1/2023

  Inozyme Pharma, Inc. (Nasdaq: INZY) today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in the Neuromuscular and Bone Panel presentation at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023, from 2:10-3:10pm ET in Boston.

• Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

  2/16/2023

  Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive topline pharmacokinetic (PK), pharmacodynamic (PD), and safety data from the ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE).

• Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023

  2/6/2023

  Inozyme Pharma, Inc. today announced that it will host an Investor and Analyst Event on Thursday, Feb. 16, 2023 at 8 a.m. ET.

• Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress

  1/9/2023

  Inozyme Pharma, Inc. today announced that it will share topline pharmacokinetic, pharmacodynamic (PK/PD) and safety data from the ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency at a virtual Investor and Analyst Event on Thursday, Feb. 16, 2023.

• Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency

  12/5/2022

  Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced the publication of an article titled “Estimation of ENPP1 Deficiency Genetic Prevalence Using a Comprehensive Literature Review and Population Databases” in the Orphanet Journal of Rare Diseases.

• Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference

  12/1/2022

  Inozyme Pharma, Inc. today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in a fireside chat at the BofA Securities Biotech SMID Cap Conference on Thursday, December 8, 2022, from 8:00-8:30am ET.

• Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates

  11/10/2022

  Inozyme Pharma, Inc. today reported financial results for the third quarter ended September 30, 2022 and provided recent business highlights.

• Inozyme Pharma to Participate in Upcoming Investor Conferences

  11/7/2022

  Inozyme Pharma, Inc. today announced that Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in the following investor conferences.

• Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial

  11/3/2022

  Inozyme Pharma, Inc. today announced the first self-administration of INZ-701 in the open-label Phase 2 extension portion of the ongoing Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency.

• Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database

  10/31/2022

  Inozyme Pharma, Inc. (Nasdaq: INZY) today announced the publication of an article titled, “ENPP1 Deficiency: A clinical update on the relevance of individual variants using a locus-specific database,” in Human Mutation.

• Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

  9/6/2022

  Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference.

• Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates

  8/15/2022

  Inozyme Pharma, Inc. today reported financial results for the second quarter ended June 30, 2022 and provided recent business highlights.

• 

  Philanthropic Donations and Debt Financings Rake in Cash for Cancer, Alzheimer's and Mental Healt...

  7/29/2022

  Money on the Move: ​​​​​​​A weekly roundup of notable funding news across biopharma industry. See who raked in funds for which diseases

• Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures

  7/26/2022

  Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that it has entered into a debt financing facility for up to $70 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.